Clinical impact and cost-effectiveness of the updated COVID-19 mRNA autumn 2023 vaccines in Germany

Conclusions: The mRNA-1273.815 vaccine can be considered cost-effective relative to the XBB.1.5 BNT162b2 vaccine and highly likely to provide more benefits and save costs compared to no vaccine in Germany, and to offer high societal return on investment.PMID:38050685 | DOI:10.1080/13696998.2023.2290388

Source: Journal of Medical Economics - December 5, 2023 Category: Health Management Authors: K Joshi S Scholz M Maschio M Kohli A Lee K Fust B Ultsch N vandeVelde E Beck Source Type: research